Can the feds negotiate Medicare Part D prices?
Can the feds negotiate Medicare Part D prices? It’s trickier than it sounds, according to experts from The Pew Charitable Trusts. Policy makers in Congress and the Centers for Medicare and Medicaid Services (CMS) would have to determine, first, which drugs would be subject to negotiation, if the discussions cover specific drugs or also formulary structures, and if negotiations apply to just one or all Part D plans. Assuming those tricky issues could be resolved (and made legal), the parties would need to devise a negotiating process, including whether and how to use arbitration if there’s no agreement.
It’s not clear that establishing such a negotiating process will save Medicare any money, but growing political pressure may lead to some kind of test of such a process, including further examination of what legislative changes may be needed to move forward. See the posting on the website of the journal Health Affairs.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.